Loading clinical trials...
Loading clinical trials...
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer - a Multicenter Prospective Observational Study
This study aims to assess overall survival, quality of life and resection rates in locally advanced pancreatic cancer
This is a multicenter pragmatic prospective observational study including Nordic hospitals treating patients with borderline resectable and locally advanced pancreatic cancer. Eligibility will be assessed at regional multidisciplinary tumor boards. Patients with borderline resectable and locally advanced (non-endocrine) pancreatic cancer according to the National Comprehensive Cancer Network (NCCN) and the International Study Group of Pancreatic Surgery (ISGPS) are eligible for inclusion. The study is observational. Quality of life will be assessed in all study participants. The primary outcomes are exploration rates, resection rates and overall survival.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Surgical Clinic at Umeå University Hospital
Umeå, Sweden
Start Date
April 19, 2022
Primary Completion Date
May 1, 2025
Completion Date
May 1, 2028
Last Updated
November 30, 2022
300
ESTIMATED participants
Lead Sponsor
Umeå University
Collaborators
NCT04485286
NCT04605913
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions